Last reviewed · How we verify
Cimetidine IV
Cimetidine is a histamine H2-receptor antagonist that reduces gastric acid secretion by blocking histamine-mediated stimulation of parietal cells.
Cimetidine is a histamine H2-receptor antagonist that reduces gastric acid secretion by blocking histamine-mediated stimulation of parietal cells. Used for Peptic ulcer disease, Gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome.
At a glance
| Generic name | Cimetidine IV |
|---|---|
| Sponsor | Bausch Health Americas, Inc. |
| Drug class | H2-receptor antagonist |
| Target | Histamine H2 receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Cimetidine competitively inhibits histamine H2 receptors on gastric parietal cells, thereby decreasing both basal and stimulated gastric acid production. This reduction in gastric acidity is used to treat and prevent peptic ulcer disease, gastroesophageal reflux disease (GERD), and other acid-related conditions. The IV formulation allows for rapid onset of action in acute clinical settings.
Approved indications
- Peptic ulcer disease
- Gastroesophageal reflux disease (GERD)
- Zollinger-Ellison syndrome
- Acute upper gastrointestinal bleeding prophylaxis
Common side effects
- Headache
- Diarrhea
- Dizziness
- Gynecomastia (with chronic use)
- Confusion (especially in elderly or renal impairment)
Key clinical trials
- Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel (PHASE2, PHASE3)
- Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (PHASE3)
- Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors (PHASE2)
- Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer (PHASE2)
- HIPEC in the Treatment of Stage IIc-IV Epithelial Ovarian Cancer After CRS (HIPECOC) (NA)
- Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX (PHASE1)
- Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill (PHASE3)
- Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cimetidine IV CI brief — competitive landscape report
- Cimetidine IV updates RSS · CI watch RSS
- Bausch Health Americas, Inc. portfolio CI